Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Heart Failure Drugs Market to Reach $12.31 Billion by 2035 as Advanced Therapies Reshape Treatment - Industry Analysis and Sales Forecast (2026-2035)

globenewswire.com
AZN AstraZeneca is mentioned as a company active in the heart failure drugs market, which is projected to grow significantly. The article does not provide specific sentiment towards AstraZeneca's performance or products. BMY Bristol Myers Squibb is listed as a company active in the heart failure drugs market, a sector expected to expand. The article does not offer specific details or sentiment regarding the company's individual performance or products. LLY Eli Lilly is identified as a participant in the heart failure drugs market, which is anticipated to grow. The article does not provide specific sentiment or performance indicators for Eli Lilly. NVO Novo Nordisk is mentioned as a company active in the heart failure drugs market. The article projects growth for this market but offers no specific sentiment or performance details for Novo Nordisk.

Global Heart Failure Drugs Market to Reach $12.31 Billion by 2035 as Advanced Therapies Reshape Treatment - Industry Analysis and Sales Forecast (2026-2035) Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Heart Failure Drugs Market by Type of Heart Failure, Type of Therapy, Type of Molecule, Route of Administration, Geographical Regions, Sales Forecast - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.

The global heart failure drugs market is projected to increase from USD 9.19 billion in 2026 to USD 12.31 billion by 2035. The forecast represents revenue generated by drugs primarily indicated for heart failure. Market growth is being supported by rising disease prevalence, an aging global population, continued pharmaceutical research and development, and increasing adoption of advanced therapeutic classes.

Heart Failure Drugs Market Growth and Trends

According to the Heart Failure Society of America, approximately 6.7 million Americans aged 20 years and older are living with heart failure, with the affected population projected to reach 10.3 million by 2040. The growing incidence of hypertension, obesity, coronary artery disease, and diabetes is further increasing demand for effective long-term treatment options.

Approved therapies include angiotensin-converting enzyme inhibitors, diuretics, angiotensin receptor blockers, aldosterone antagonists, and beta-blockers. More recently, angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors, and mineralocorticoid receptor antagonists have expanded the treatment landscape by addressing cardiac remodeling, fluid overload, and neurohormonal dysregulation.

Pharmaceutical companies are also investing in novel mechanisms of action, combination regimens, precision medicine, and advanced drug-delivery technologies. Increasing clinical evidence that newer therapies can reduce mortality and heart failure-related hospitalization is expected to support broader adoption through 2035.

Key Heart Failure Drugs Market Insights

Market Drivers and Development Challenges

The expanding geriatric population is a major driver of the heart failure therapeutics market, particularly because prevalence increases significantly among people aged 70 years and older. Strong clinical outcomes associated with SGLT2 inhibitors and ARNIs are also encouraging the adoption of newer treatment strategies, including multidrug regimens designed to improve survival and reduce hospitalization.

Despite this progress, heart failure drug development remains affected by high clinical attrition rates, insufficient efficacy, limited target specificity, and safety concerns. Low approval rates for new cardiovascular molecular entities, expensive large-scale clinical trials, stringent regulatory requirements, patient recruitment difficulties, and restricted funding can delay the commercialization of promising therapies.

Heart Failure Drugs Market Segment Analysis

Chronic heart failure is expected to generate more than 95% of market revenue, supported by high prevalence, lifelong treatment requirements, and the continuing need to control symptoms and disease progression. Empagliflozin, marketed as Jardiance, generated approximately USD 4.4 billion in sales in 2025, highlighting the commercial potential of chronic heart failure therapies.

Small molecules currently account for more than 95% of market revenue. Their dominance is supported by established efficacy, oral availability, and widespread use of beta-blockers, ACE inhibitors, ARBs, and SGLT2 inhibitors. However, biologics are projected to record a CAGR of 52.0% through 2035 as developers increasingly target genetic, molecular, and inflammatory pathways.

Oral therapies contribute more than 95% of current revenue because of their convenience, suitability for long-term outpatient treatment, and favorable patient adherence. Intramyocardial administration is forecast to grow at a CAGR of 34.9%, driven by its potential to deliver therapeutic agents directly to cardiac tissue.

Monotherapies retain the largest revenue share due to their established role in clinical practice, documented outcomes, and cost-effectiveness. Combination therapies are expected to grow at a CAGR of 34.4%, supported by increasing use of regimens incorporating ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.

Regional Heart Failure Drugs Market Outlook

North America accounts for more than 40% of the global heart failure drugs market in 2026 and is expected to maintain its leadership through 2035. The region benefits from advanced healthcare infrastructure, favorable reimbursement, high disease awareness, substantial cardiovascular research investment, and a well-established biopharmaceutical industry. The United States remains a principal center for clinical development and commercialization.

Asia-Pacific is forecast to achieve the strongest regional growth, supported by population aging, a rising cardiovascular disease burden, improving healthcare access, and expanding pharmaceutical investment. In the United Arab Emirates, initiatives by the Emirates Drug Establishment to reduce retail prices for 168 pharmaceutical products, including advanced therapies used for chronic heart muscle failure, are expected to improve treatment accessibility.

Market Segmentation

Companies Active in the Heart Failure Drugs Market

Companies featured in the competitive landscape include AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Corteria Pharmaceuticals, Cytokinetics, Eli Lilly, Hyloris Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals, Novo Nordisk, Sardocor, StemCardia, Tasly Pharmaceuticals, and Tenaya Therapeutics.

Research Coverage

The market report provides revenue forecasts and opportunity analysis by heart failure type, therapy, molecule, route of administration, and geography. It also evaluates the clinical pipeline, mechanisms of action, target patient populations, leading developers, completed and ongoing clinical trials, drug discontinuations, competitive activity, and factors influencing market growth.

The findings incorporate primary research discussions with cardiologists, medical professors, heart failure specialists, clinical researchers, and trial leaders from organizations in North America, Europe, and Asia. The report is designed to help pharmaceutical companies, investors, healthcare organizations, and new market entrants assess emerging opportunities and develop evidence-based commercial strategies.

Report Benefits

For more information about this report visit https://www.researchandmarkets.com/r/5iuhyt

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.